These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
232 related articles for article (PubMed ID: 35294453)
1. Phenomenological assessment of psychedelics induced experiences: Translation and validation of the German Challenging Experience Questionnaire (CEQ) and Ego-Dissolution Inventory (EDI). Dworatzyk K; Jansen T; Schmidt TT PLoS One; 2022; 17(3):e0264927. PubMed ID: 35294453 [TBL] [Abstract][Full Text] [Related]
2. Ego-Dissolution and Psychedelics: Validation of the Ego-Dissolution Inventory (EDI). Nour MM; Evans L; Nutt D; Carhart-Harris RL Front Hum Neurosci; 2016; 10():269. PubMed ID: 27378878 [TBL] [Abstract][Full Text] [Related]
3. LSD, madness and healing: Mystical experiences as possible link between psychosis model and therapy model. Wießner I; Falchi M; Palhano-Fontes F; Feilding A; Ribeiro S; Tófoli LF Psychol Med; 2023 Mar; 53(4):1151-1165. PubMed ID: 34253268 [TBL] [Abstract][Full Text] [Related]
4. Development of the Psychological Insight Questionnaire among a sample of people who have consumed psilocybin or LSD. Davis AK; Barrett FS; So S; Gukasyan N; Swift TC; Griffiths RR J Psychopharmacol; 2021 Apr; 35(4):437-446. PubMed ID: 33427007 [TBL] [Abstract][Full Text] [Related]
5. Naturalistic use of psychedelics is related to emotional reactivity and self-consciousness: The mediating role of ego-dissolution and mystical experiences. Orłowski P; Ruban A; Szczypiński J; Hobot J; Bielecki M; Bola M J Psychopharmacol; 2022 Aug; 36(8):987-1000. PubMed ID: 35475373 [TBL] [Abstract][Full Text] [Related]
7. Adaptation and latent structure of the Brazilian version of the Ego Dissolution Inventory (EDI-BR): an exploratory study. Bienemann B; Longo MSC; Ridolfi M; Multedo M; Cruz LVM; Schenberg E; Tófoli LF; Mograbi DC Trends Psychiatry Psychother; 2024; 46():e20220491. PubMed ID: 36283045 [TBL] [Abstract][Full Text] [Related]
8. Development of the Japanese version of the Ego-Dissolution Inventory (EDI). Kusudo K; Tani H; Yonezawa K; Nakajima S; Nour MM; Carhart-Harris R; Uchida H Neuropsychopharmacol Rep; 2024 Mar; 44(1):292-297. PubMed ID: 38318991 [TBL] [Abstract][Full Text] [Related]
9. The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms. Barrett FS; Bradstreet MP; Leoutsakos JS; Johnson MW; Griffiths RR J Psychopharmacol; 2016 Dec; 30(12):1279-1295. PubMed ID: 27856683 [TBL] [Abstract][Full Text] [Related]
10. The revival of the psychedelic experience scale: Revealing its extended-mystical, visual, and distressing experiential spectrum with LSD and psilocybin studies. Stocker K; Hartmann M; Ley L; Becker AM; Holze F; Liechti ME J Psychopharmacol; 2024 Jan; 38(1):80-100. PubMed ID: 37905369 [TBL] [Abstract][Full Text] [Related]
11. Linkages between Psychedelics and Meditation in a Population-Based Sample in the United States. Simonsson O; Goldberg SB J Psychoactive Drugs; 2023; 55(1):11-18. PubMed ID: 35000559 [TBL] [Abstract][Full Text] [Related]
12. Finding the self by losing the self: Neural correlates of ego-dissolution under psilocybin. Lebedev AV; Lövdén M; Rosenthal G; Feilding A; Nutt DJ; Carhart-Harris RL Hum Brain Mapp; 2015 Aug; 36(8):3137-53. PubMed ID: 26010878 [TBL] [Abstract][Full Text] [Related]
14. Phenomenology, Structure, and Dynamic of Psychedelic States. Preller KH; Vollenweider FX Curr Top Behav Neurosci; 2018; 36():221-256. PubMed ID: 28025814 [TBL] [Abstract][Full Text] [Related]
15. Emotional breakthrough and psychedelics: Validation of the Emotional Breakthrough Inventory. Roseman L; Haijen E; Idialu-Ikato K; Kaelen M; Watts R; Carhart-Harris R J Psychopharmacol; 2019 Sep; 33(9):1076-1087. PubMed ID: 31294673 [TBL] [Abstract][Full Text] [Related]
16. Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin. Barrett FS; Johnson MW; Griffiths RR J Psychopharmacol; 2015 Nov; 29(11):1182-90. PubMed ID: 26442957 [TBL] [Abstract][Full Text] [Related]
17. Me, myself, bye: regional alterations in glutamate and the experience of ego dissolution with psilocybin. Mason NL; Kuypers KPC; Müller F; Reckweg J; Tse DHY; Toennes SW; Hutten NRPW; Jansen JFA; Stiers P; Feilding A; Ramaekers JG Neuropsychopharmacology; 2020 Nov; 45(12):2003-2011. PubMed ID: 32446245 [TBL] [Abstract][Full Text] [Related]
18. Translation and Initial Psychometric Evaluation of Spanish Versions of Three Psychedelic Acute Effects Measures: Mystical, Challenging, and Insight Experiences. Davis AK; Timmermann C; Ortiz Bernal AM; Lancelotta R; Nayak S; Sepeda ND; Nikolaidis A; Griffiths RR J Psychoactive Drugs; 2023 Jul; ():1-11. PubMed ID: 37449499 [TBL] [Abstract][Full Text] [Related]
19. Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression. Roseman L; Nutt DJ; Carhart-Harris RL Front Pharmacol; 2017; 8():974. PubMed ID: 29387009 [No Abstract] [Full Text] [Related]